Aakash Desai

Aakash Desai Highlights New Study on BRAF-Mutated NSCLC: Personalization Over One-Size-Fits-All

Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on X about recent article Marcel Wiesweg and colleagues authored:

“In JTO and JTO CRR BRAF-mutated NSCLC.
1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:
– Similar OS outcomes
– PD-L1 status and gender influence prognosis
Personalization > one-size-fits-all”

BRAF-Mutated NSCLC

Title: Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

Journal: Journal of Thoracic Oncology

Authors: Marcel Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld, Maximilian Rost, Christin Assmann, Franziska Herster, Moritz Hilbrandt, Frank Griesinger, Anna Kron, Julia Roeper, Franziska Glanemann, Cornelia Kropf-Sanchen, Martin Reck, Jonas Kulhavy, Albrecht Stenzinger, Jürgen Wolf, Martin Sebastian, Martin Schuler, Martin Wermke, Nikolaj Frost, Hans-Georg Kopp, Petros Christopoulos, Matthias Scheffler

Read Full Article.

Aakash Desai Highlights New Study on BRAF-Mutated NSCLC: Personalization Over One-Size-Fits-All

More posts featuring Aakash Desai on OncoDaily.

 

Albrecht Stenzinger Ali Alaffas Anna Kron Anna Rasokat BRAF-Mutated NSCLC cancer Christin Assmann Cornelia Kropf-Sanchen Felix Carl Saalfeld Frank Griesinger Franziska Glanemann Franziska Herster Hans-Georg Kopp Jonas Kulhavy Julia Roeper Jürgen Wolf Marcel Wiesweg Martin Reck Martin Schuler Martin Sebastian Martin Wermke Matthias Scheffler Maximilian Rost Moritz Hilbrandt Nikolaj Frost NSCLC OncoDaily Oncology Petros Christopoulos